✨ Health Notices




22 DECEMBER 2005 NEW ZEALAND GAZETTE, No. 210 5369

Appointment of Compulsory Care Co-ordinators

Under section 140 of the Intellectual Disability (Compulsory Care and Rehabilitation) Act 2003, I appoint the following person as a compulsory care co-ordinator for the named geographical and operational area listed below.

Central Region including Manawatu-Wanganui, Palmerston North, Hawke’s Bay, Wairarapa and Wellington:

Frank Ngatai.

The appointment takes effect on the date this notice is published in the New Zealand Gazette, and ends on 12 December 2010.

Dated at Wellington this 12th day of December 2005.

KAREN O. POUTASI (DR), Director-General of Health.

go8453


Medicines Act 1981

Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:

Schedule

Product: Fexofenadine
Active Ingredient: Fexofenadine hydrochloride 120mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Douglas Pharmaceuticals Limited
Manufacturer: Ranbaxy Laboratories Limited, Dewas, Madhya Pradesh, India

Product: Fexofenadine
Active Ingredient: Fexofenadine hydrochloride 180mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Douglas Pharmaceuticals Limited
Manufacturer: Ranbaxy Laboratories Limited, Dewas, Madhya Pradesh, India

Product: Inspra
Active Ingredient: Eplerenone 25mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Pfizer New Zealand Limited
Manufacturer: Pfizer Pharmaceuticals LLC, Caguas, Puerto Rico

Product: Inspra
Active Ingredient: Eplerenone 50mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Pfizer New Zealand Limited
Manufacturer: Pfizer Pharmaceuticals LLC, Caguas, Puerto Rico

Product: Venofer
Active Ingredient: Iron sucrose 540mg/mL equivalent to iron 20mg/mL
Dosage Form: Solution for injection
New Zealand Sponsor: Baxter Healthcare Limited
Manufacturer: ALTANA Pharma AG, Singen, Germany

Dated this 19th day of December 2005.

KAREN MITCHELL, Acting Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).

go8673


Renewal of Provisional Consent to the Distribution of a New Medicine

Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:

Schedule

Product: Viramune
Active Ingredient: Nevirapine hemihydrate 10.35mg/mL equivalent 10mg/mL nevirapine
Dosage Form: Oral suspension
New Zealand Sponsor: Boehringer Ingelheim (NZ) Limited
Manufacturer: Boehringer Ingelheim Roxane Inc, Columbus, Ohio, United States of America

Note: This consent is valid for two years from 2 March 2006.

Dated this 19th day of December 2005.

KAREN MITCHELL, Acting Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).

go8672



Next Page →



Online Sources for this page:

VUW Te Waharoa PDF NZ Gazette 2005, No 210


Gazette.govt.nz PDF NZ Gazette 2005, No 210





✨ LLM interpretation of page content

πŸ₯ Appointment of Compulsory Care Co-ordinator

πŸ₯ Health & Social Welfare
12 December 2005
Compulsory Care Co-ordinator, Appointment, Central Region, Intellectual Disability
  • Frank Ngatai, Appointed Compulsory Care Co-ordinator

  • Karen O. Poutasi (Dr), Director-General of Health

πŸ₯ Consent to Distribution of New Medicines

πŸ₯ Health & Social Welfare
19 December 2005
Medicines, Distribution, Fexofenadine, Inspra, Venofer
  • Karen Mitchell, Acting Deputy Director-General, Public Health

πŸ₯ Renewal of Provisional Consent for New Medicine

πŸ₯ Health & Social Welfare
19 December 2005
Medicine, Provisional Consent, Viramune, Nevirapine
  • Karen Mitchell, Acting Deputy Director-General, Public Health